Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin with Allogeneic Stem Cell Transplant in Relapsed/Refractory NHL
NCT00807196Phase 2Unknown
- Sponsor
- Hôpital Maisonneuve-Rosemont
- Start
- Sep 2008
- Primary completion
- Dec 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in non-Hodgkin lymphoma (NHL), sponsored by Hôpital Maisonneuve-Rosemont. Primary endpoints: Engraftment at 1 year, Chimerism at 1 year and 2 more. Status: unknown.
02
Drugs
ibritumomab tiuxetan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00807196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00807196.